Hyperphosphorylated paratarg-7: A new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenström macroglobulinemia

Blood

Volumn 117, Issue 10, 2011, Pages 2918-2923

  Grass, Sandra ^a   Preuss, Klaus Dieter ^a   Wikowicz, Alexandra ^a   Terpos, Evangelos ^b   Ziepert, Marita ^c   Nikolaus, Diana ^a   Yang, Yin ^a   Fadle, Natalie ^a   Regitz, Evi ^a   Dimopoulos, Meletios A ^b   Treon, Steven P ^d   Hunter, Zachary R ^d   Pfreundschuh, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; IMMUNOGLOBULIN M; PARAPROTEIN; PARATARG 7 PROTEIN; PHOSPHATASE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DOMINANT INHERITANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLICULAR LYMPHOMA; GENE FREQUENCY; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MELANOMA; MONOCLONAL IMMUNOGLOBULINEMIA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; RISK FACTOR; WALDENSTROEM MACROGLOBULINEMIA;

EID: 79953105788     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-09-306076     Document Type: Article

References (28)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008.
2. Landgren O, Kristinsson SY, Goldin LR, et al. Risk of plasma-cell and lymphoproliferative disorders among 14,621 first-degree relatives of 4,458 patients with monoclonal gammopathy of undetermined significance (MGUS) in Sweden. Blood. 2009;114(4):791-795.
3. Koshiol J, Gridley G, Engels EA, McMaster ML, Landgren O. Chronic immune stimulation and subsequent Waldenstrom macroglobulinemia. Arch Intern Med. 2008;168(17):1903-1909.
4. McMaster ML, Goldin LR, Bai Y, et al. Genomewide linkage screen for Waldenstrom macroglobulinemia susceptibility loci in high-risk families. Am J Hum Genet. 2006;79(4):695-701. (Pubitemid 44452746)
5. McMaster ML, Csako G, Giambarresi TR, et al. Long-term evaluation of three multiple-case Waldenstrom macroglobulinemia families. Clin Cancer Res. 2007;13(17):5063-5069. (Pubitemid 47502071)
6. Treon SP, Hunter ZR, Aggarwal A, et al. Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol. 2006;17(3):488-494.
7. Kristinsson SY, Bjorkholm M, Goldin LR, et al. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. Blood. 2008;112(8):3052-3056.
8. Aoki H, Takishita M, Kosaka M, Saito S. Frequent somatic mutations in D and/or JH segments of Ig gene in Waldenstrom's macroglobulinemia and chronic lymphocytic leukemia (CLL) with Richter's syndrome but not in common CLL. Blood. 1995;85(7):1913-1919.
9. Wagner SD, Martinelli V, Luzzatto L. Similar patterns of V kappa gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytic leukemia, Waldenstrom's macroglobulinemia, and myeloma. Blood. 1994;83(12):3647-3653.
10. Martin-Jimenez P, Garcia-Sanz R, Balanzategui A, et al. Molecular characterization of heavy chain immunoglobulin gene rearrangements inWaldenstrom's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Haematologica. 2007;92(5):635-642. (Pubitemid 350144265)
11. Royer RH, Koshiol J, Giambarresi TR, et al. Differential characteristics of Waldenstrom macroglobulinemia according to patterns of familial aggregation. Blood. 2010;115(22):4464-4471.
12. Goldin LR, Landgren O. Autoimmunity and lymphomagenesis. Int J Cancer. 2009;124(7):1497-1502.
13. Linet MS, Humphrey RL, Mehl ES, et al. A casecontrol and family study of Waldenstrom's macroglobulinemia. Leukemia. 1993;7(9):1363-1369. (Pubitemid 23291076)
14. Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 2006;98(1):51-60. (Pubitemid 43057092)
15. Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 2007;297(18):2010-2017. (Pubitemid 46740353)
16. Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A. 1995;92(25):11810-11813. (Pubitemid 26014201)
17. Preuss KD, Held G, Kubuschok B, et al. Identification of antigenic targets of paraproteins by expression cloning does not support a causal role of chronic antigenic stimulation in the pathogenesis of multiple myeloma and MGUS. Int J Cancer. 2007;121(2):459-461. (Pubitemid 46917718)
18. Wang Y, Morrow JS. Identification and characterization of human SLP-2, a novel homologue of stomatin (band 7.2b) present in erythrocytes and other tissues. J Biol Chem. 2000;275(11):8062-8071. (Pubitemid 30159719)
19. Grass S, Preuss K-D, Ahlgrimm A, et al. Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study. Lancet Oncol. 2009;10:950-956.
20. Preuss KD, Pfreundschuh M, Ahlgrimm M, et al. A frequent target of paraproteins in the sera of patients with multiple myeloma and MGUS. Int J Cancer. 2009;125(3):656-661.
21. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17(12):2257-2317. (Pubitemid 38072572)
22. Brochet X, Lefranc MP, Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 2008; 36(Web Server issue):W503-W508.
23. Lefranc MP, Giudicelli V, Ginestoux C, et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res. 2009;37(Database issue):D1006-D1012.
24. Kristinsson SY, Koshiol J, Bjorkholm M, et al. Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. J Natl Cancer Inst. 2010;102(8):557-567.
25. Lynch HT, Ferrara K, Barlogie B, et al. Familial myeloma. N Engl J Med. 2008;359(2):152-157. (Pubitemid 351962038)
26. Prabhala RH, Neri P, Bae JE, et al. Dysfunctional T regulatory cells in multiple myeloma. Blood. 2006;107(1):301-304. (Pubitemid 43053555)
27. Mohammed F, Cobbold M, Zarling AL, et al. Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self. Nat Immunol. 2008;9(11):1236-1243.
28. Meyer VS, Drews O, Gunder M, Hennenlotter J, Rammensee HG, Stevanovic S. Identification of natural MHC class II presented phosphopeptides and tumor-derived MHC class I phospholigands. J Proteome Res. 2009;8(7):3666-3674.